[HTML][HTML] Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease
S De Iudicibus, R Franca, S Martelossi… - World journal of …, 2011 - ncbi.nlm.nih.gov
Natural and synthetic glucocorticoids (GCs) are widely employed in a number of
inflammatory, autoimmune and neoplastic diseases, and, despite the introduction of novel …
inflammatory, autoimmune and neoplastic diseases, and, despite the introduction of novel …
Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis
O Teuffel, SP Kuster, SP Hunger, V Conter, J Hitzler… - Leukemia, 2011 - nature.com
This systematic review and meta-analysis compared the efficacy and toxicity of
dexamethasone (DEX) versus prednisone (PRED) for induction therapy in childhood acute …
dexamethasone (DEX) versus prednisone (PRED) for induction therapy in childhood acute …
[HTML][HTML] Pharmacogenomic and pharmacotranscriptomic profiling of childhood acute lymphoblastic leukemia: paving the way to personalized treatment
Personalized medicine is focused on research disciplines which contribute to the
individualization of therapy, like pharmacogenomics and pharmacotranscriptomics. Acute …
individualization of therapy, like pharmacogenomics and pharmacotranscriptomics. Acute …
[HTML][HTML] Epigenetic modifications and glucocorticoid sensitivity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
Abstract Background Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a
debilitating idiopathic disease characterized by unexplained fatigue that fails to resolve with …
debilitating idiopathic disease characterized by unexplained fatigue that fails to resolve with …
Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy
L Mei, EP Ontiveros, EA Griffiths, JE Thompson… - Blood reviews, 2015 - Elsevier
Acute lymphoblastic leukemia (ALL) is a relatively rare disease in adults accounting for no
more than 20% of all cases of acute leukemia. By contrast with the pediatric population, in …
more than 20% of all cases of acute leukemia. By contrast with the pediatric population, in …
Pharmacogenetics of childhood acute lymphoblastic leukemia
E Lopez-Lopez, A Gutierrez-Camino… - …, 2014 - Taylor & Francis
Acute lymphoblastic leukemia (ALL) is the major pediatric cancer in developed countries.
Although treatment outcome has improved owing to advances in chemotherapy, there is still …
Although treatment outcome has improved owing to advances in chemotherapy, there is still …
Genetic variation in the glucocorticoid pathway involved in interindividual differences in the glucocorticoid treatment
QQ Song, WY Xie, YJ Tang, J Zhang, J Liu - Pharmacogenomics, 2017 - Taylor & Francis
Glucocorticoids (GCs) are widely used for treating asthma, rheumatoid arthritis, nephrotic
syndrome, acute lymphoblastic leukemia and other autoimmune diseases. However, in a …
syndrome, acute lymphoblastic leukemia and other autoimmune diseases. However, in a …
[PDF][PDF] Association between N363S and BclI polymorphisms of the glucocorticoid receptor gene (NR3C1) and glucocorticoid side effects during childhood acute …
MK Cihan, HG Karabulut, NY Kutlay… - Turkish Journal of …, 2017 - jag.journalagent.com
Objective: Glucocorticoids (GCs) are the key drugs for the treatment of pediatric acute
lymphoblastic leukemia (ALL). Herein, investigation of the relationship between the N363S …
lymphoblastic leukemia (ALL). Herein, investigation of the relationship between the N363S …
Implementation of pharmacogenetics to individualize treatment regimens for children with acute lymphoblastic leukemia
Despite major advances in the management and high cure rates of childhood acute
lymphoblastic leukemia (ALL), patients still suffer from many drug-induced toxicities …
lymphoblastic leukemia (ALL), patients still suffer from many drug-induced toxicities …
Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol
Drug-related toxicities represent an important clinical concern in chemotherapy, genetic
variants could help tailoring treatment to patient. A pharmacogenetic multicentric study was …
variants could help tailoring treatment to patient. A pharmacogenetic multicentric study was …